Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.11. | Senti Biosciences GAAP EPS of -$6.31 | 3 | Seeking Alpha | ||
12.11. | Intel says it lowered stakes in Astera Labs, Joby Aviation, Senti Biosciences | 27 | Seeking Alpha | ||
SENTI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
26.10. | Senti Biosciences faces nasdaq delisting over audit rule | 3 | Investing.com | ||
25.10. | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.09. | Senti Biosciences, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
03.09. | Senti Biosciences, Inc.: Senti Bio to Participate in Upcoming Investor Conferences | 2 | GlobeNewswire (USA) | ||
14.08. | Senti Biosciences GAAP EPS of -$2.45 | 2 | Seeking Alpha | ||
13.08. | Senti Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.08. | Senti Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
13.08. | Senti Biosciences, Inc.: Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights | 232 | GlobeNewswire (Europe) | - Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML - - Commencement of $8 million grant award from CIRM... ► Artikel lesen | |
05.08. | Senti Biosciences, Inc.: Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 | 4 | GlobeNewswire (USA) | ||
16.07. | Senti Biosciences to effect 1-for-10 reverse stock split for Nasdaq compliance | 3 | Seeking Alpha | ||
16.07. | Senti Biosciences, Inc.: Senti Bio Announces Reverse Stock Split | 114 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using... ► Artikel lesen | |
12.07. | Senti Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
02.07. | Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks | 49 | MarketBeat | ||
01.07. | Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening? | 11 | Benzinga.com | ||
01.07. | Senti Biosciences, Inc.: Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy | 10 | GlobeNewswire (USA) | ||
25.06. | Why Is Senti Biosciences (SNTI) Stock Up 32% Today? | 4 | InvestorPlace | ||
13.05. | Senti Biosciences, Inc.: Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia | 142 | GlobeNewswire (Europe) | - SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy - - Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 - SOUTH SAN... ► Artikel lesen | |
09.05. | Senti Biosciences, Inc.: Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights | 795 | GlobeNewswire (Europe) | - First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML"), on track for the second quarter of 2024 - SOUTH SAN FRANCISCO, Calif., May 09, 2024... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
ONCOLYTICS BIOTECH | 0,915 | -3,17 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
ASSERTIO | 0,936 | -3,08 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
VIR BIOTECHNOLOGY | 7,120 | +2,45 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
TRAVERE THERAPEUTICS | 17,900 | +1,70 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
ARVINAS | 25,850 | +2,95 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
BIO-PATH | 0,810 | +1,38 % | Bio-Path-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,79 US-Dollar |